jRCT2051240117招募中不适用
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Children Diagnosed With Severe Von Willebrand Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 24
- 主要终点
- Annualized Bleeding Rate (ABR) for Spontaneous or Traumatic Bleeding Episodes as Assessed by Investigator During Prophylactic Treatment With rVWF
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- No limit 至 17age old under（—）
- 性别
- All
入选标准
- •The participant has a documented diagnosis of severe VWD (baseline von Willebrand factor ristocetin cofactor activity [VWF:RCo] <20 internal units per deciliter [IU/dL]) with a history of substitution therapy with VWF concentrate required to control bleeding and a diagnosis of VWD type 1, type 2 (2A, 2B, 2M, 2N), or type
- •Diagnosis is confirmed, when applicable, by genetic testing and/or by multimer analysis, which may be documented in participant's history or at screening.
- •The participant is <18 years of age at the time of screening.
- •Prescreening treatment requirements:
- •The participant has been receiving OD therapy with VWF products for at least 12 months (for participants >=2 years of age) prior to screening, has experienced at least 1 VWF-treated bleeding event during (excluding menorrhagia/heavy menstrual bleeding [HMB], as applicable) in the last 12 months, and prophylactic treatment is recommended by the investigator (Prior OD participants); or
- •The participant has been receiving prophylactic treatment with pdVWF products for at least 12 months prior to screening (for participants >=2 years of age) and switching to prophylaxis with rVWF is recommended by the investigator (Switch participants).
- •For participants <2 years of age, the required duration for prior OD therapy with VWF products or for prior prophylactic treatment with pdVWF products is at least 6 months. Prior OD participants <2 years of age should have experienced at least 1 VWF-treated bleeding event during the last 6 months based on medical records and be recommended to receive prophylactic treatment by the investigator.
- •For participants >=2 years of age, the participant has available records that reliably evaluate type, frequency, severity, and treatment of BEs for at least 12 months preceding enrollment. For participants <2 years of age, the participant has available records that reliably evaluate type, frequency, severity and treatment of BEs for at least 6 months preceding enrollment.
- •If >=12 years old at the time of screening, the participant has a body mass index (BMI) >=15 but <40 kilogram per square meter (kg/m^2). If >=2 to <12 years old at the time of screening, the participant has a BMI of >=5th and <95th percentile (per Centers for Disease Control and Prevention [CDC] clinical charts). For younger participants who are <2 years old, the "weight-for-age" clinical charts (5th to 95th percentile) provided by the CDC should be utilized to ensure the participant has a body weight of >=5th and <95th percentile based on gender (for clinical charts provided by CDC, refer to: https://www.cdc.gov/growthcharts/clinical_charts.htm).
- •Female participants of childbearing potential (that is, had onset of menses/reached puberty) must have a negative blood/urine pregnancy test result at screening and agree to employ highly effective birth control measures for the duration of their participation in the study.
- •The participant has voluntarily provided assent (if appropriate) and the legally authorized representative(s) has provided informed consent.
- •The participant and/or legally authorized representative is willing and able to comply with the requirements of the protocol, which should also be confirmed based on a prescreening evaluation held between the investigator and the sponsor to ensure no eminent risk is present that could challenge the participant's compliance with the study requirements.
排除标准
- •The participant has been diagnosed with pseudo VWD or another hereditary or acquired coagulation disorder other than VWD (example, qualitative and quantitative platelet disorders or elevated prothrombin time/international normalized ratio 1.4).
- •The participant has a history or presence of a VWF inhibitor at screening.
- •The participant has a history or presence of an factor VIII (FVIII) inhibitor with a titer >=0.4 Bethesda units (BU) (by the Nijmegen-modified Bethesda assay) or >=0.6 BU (by the Bethesda assay).
- •The participant has a known hypersensitivity to any of the components of the study drugs, such as mouse or hamster proteins.
- •The participant has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies, or animal allergies.
- •The participant has a medical history of a thromboembolic event.
- •The participant is human immunodeficiency virus (HIV)-positive with an absolute helper T cell (CD4) count <200 per cubic millimeter or microliter (/mm^3).
- •The participant has been diagnosed with significant liver disease per the investigator's medical assessment of the participant's current condition or medical history or as evidenced by, but not limited to, any of the following: serum alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN), hypoalbuminemia, portal vein hypertension (example, presence of otherwise unexplained splenomegaly, history of esophageal varices), or liver cirrhosis classified as Child-Pugh class B or C.
- •The participant has been diagnosed with renal disease, with a serum creatinine level >=2.5 milligram per deciliter (mg/dL).
- •The participant has a platelet count <100,000 per milliliter (/mL) at screening (because participants with type 2B VWD are considered eligible for this study, for participants with type 2B VWD, platelet count[s] at screening will be evaluated in consultation with the sponsor, taking into consideration historical trends in platelet counts and the investigator's medical assessment of the participants condition).
- •The participant has been treated with an immunomodulatory drug, excluding topical treatment (example, ointments, nasal sprays), within 30 days prior to signing the informed consent (or assent, if appropriate).
- •The participant is pregnant or lactating at the time of enrollment.
- •The participant has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
- •The participant has participated in another clinical study involving another IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
- •The participant has not received OD or prophylactic treatment with a VWF product prior to this study.
- •The participant has a progressive fatal disease and/or life expectancy of less than 15 months.
- •The participant is already scheduled for a surgical intervention that will have to be performed while the participant is participating in the study.
- •The participant is unable to complete screening procedures and/or comply with the requirements of the protocol in the opinion of the investigator, based on the joint prescreening evaluation held between the investigator and the sponsor.
- •The participant has a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
- •The participant is member of the study team or in a dependent relationship with one of the study team members, which includes close relatives (that is, children, partner/spouse, siblings, and parents) as well as employees.
结局指标
主要结局
Annualized Bleeding Rate (ABR) for Spontaneous or Traumatic Bleeding Episodes as Assessed by Investigator During Prophylactic Treatment With rVWF
时间窗: 12 months
ABR during the study compared to historical ABR for each participant for both spontaneous and traumatic bleeding episodes as classified by the investigator during prophylactic treatment with rVWF will be reported.
次要结局
未报告次要终点
研究者
相似试验
Enrolling By Invitation
不适用
Von Willebrand Factor Antigen and Functions, Factor VIII activity and Fibrinogen Levels were Significantly Increased in Patients with Chronic Kidney DiseaseChronic kidney disease without renal replacement therapychronic kidney disease,bleeding,VWF,thrombosisTCTR20160318001Siriraj Institutional Review Board Certificate of Approval252
已完成
1 期
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand DiseaseVon Willebrand DiseaseNCT00816660Baxalta now part of Shire32
已完成
不适用
Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac ProcedureAortic StenosisHeart FailureNCT02628509University Hospital, Lille500
招募中
Unknown
To study the usefulness of von willibrand factor to ADAMTS-13 ratio as a predictor of development of extrahepatic organ failure in acute on chronic liver failure patients.CTRI/2023/10/058349Institute of Liver and Biliary Sciences
已完成
3 期
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing SurgeryVon Willebrand DiseaseNCT02283268Baxalta now part of Shire24